What Happens When You’re Just Mind Blanking
December 27, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
Clofezone, rabeprazole
Class :
Gastrointestinal agent, Antiulcer agents, Proton pump inhibitor
Brand Name :
No Data Available.
Synonyms :
Clofezone, rabeprazole
Class :
Gastrointestinal agent, Antiulcer agents, Proton pump inhibitor
patients undergoing anesthesia:
20
mg
Orally
on the night before surgery and 20 mg on the morning of surgery
Initial:
20
mg
Orally
once a day
8
weeks
or longer depending on the improvement of symptoms
20
mg
Orally
once a day
8
weeks
15
mg
Orally
once a day
4
weeks
Maintenance: 15 mg once daily
30
mg
Orally
once a day
8
weeks
30
mg
Orally
3 times a day
with amoxicillin 1000 mg 3 times a day for 14 days
Or
30 mg twice a day with amoxicillin 1000mg and clarithromycin 500 mg twice a day for 10 to 14 days
NSAID-associated gastric ulcer:
Prevention regimen: 15 mg orally once a day for 15 weeks
Treatment: 30 mg orally once a day for 8 weeks
Stress ulcer prophylaxis in critically ill patients:
30 mg orally once a day until the risk factors are resolved
Initial:
20
mg
once a day
The dose can be increased to 20 to 40 mg twice a day if symptoms persist after the initial dose
Children < 11 years (<30kg):
15
mg
Orally
once a day
>30kg: 30 mg orally once a day
Children > 12 years:
30 mg orally once a day
Gastro Esophageal Reflux Disease (GERD)
Infants:
1 - 2
mg/kg
Orally
once a day
Children > 12 years and adolescents: 0.7 to 3 mg/kg orally once a day
Or
Infants: 7.5 mg orally twice a day
Children < 11 years:
<30 kg: 15 mg orally once a day
>30 kg: 30 mg orally once a day
Children >12 years: 15 mg orally once a day
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
it may decrease the serum concentration of belumosudil
may decrease the serum concentration and decrease in the efficacy
rabeprazole increases the effect of fedratinib and vice versa
it may decrease the absorption of Levoketoconazole
they decrease the concentration of active metabolites of infigratinib in the serum
the serum concentration of acalabrutinib may be reduced by Inhibitors of the Proton Pump (PPIs and PCABs)
When bacampicillin is combined with rabeprazole, bacampicillin absorption and blood levels decrease by stomach acid reduction.
when both drugs are combined, there may be an increased risk of hypomagnesemia
it may decrease the serum concentration of Atazanavir
may decrease the therapeutic effect
This could lead to a reduction in concentration serum of mycophenolate
Action and Spectrum
It is a medication that falls into the category of proton pump inhibitors (PPIs). It works by binding to the proton pump in gastric parietal cells, ultimately reducing acid secretion. This oral drug is commonly used to treat conditions linked to acid overproduction in the stomach.
Frequency defined
1-10 %
Pain (3%)
Constipation (2%)
Flatulence (3%)
Pharyngitis (3%)
Diarrhea (2-5%)
Headache (2-10%)
Abdominal pain (4%)
<1%
Hypokalemia
Sudden death
Leukocytosis
Hypomagnesemia
Angioedema
Toxic epidermal necrolysis
Migraine
Agranulocytosis
Alopecia
Rhabdomyolysis
Abnormal taste
Osteoporosis related fracture
Erythema multiforme
Chest pain
Delirium
Jaundice
Leukopenia
Anemia
Stevens-Johnson syndrome
Agitation
Hyponatremia
Postmarketing reports
Disorders affecting the renal and urinary systems: Interstitial nephritis, erectile dysfunction
Disorders related to metabolism and nutrition: Hyperammonemia
Disorders of the blood and lymphatic system: Hemolytic anemia, pancytopenia, thrombocytopenia
Disorders affecting the respiratory, thoracic, and mediastinal regions: Interstitial pneumonia
Deficiency condition: Cyanocobalamin (vitamin B-12) deficiency
Investigative findings: Increases in prothrombin time/INR (in patients treated with concomitant warfarin), TSH elevations
Disorders of the nervous system: Coma
Disorders of the ear and labyrinth: Vertigo
Disorders of the eye: Blurred vision
Infections and infestations: Clostridium difficile-associated diarrhea
Disorders of the psyche: Disorientation
Disorders of the immune system: Anaphylaxis, toxic epidermal necrolysis (some fatal), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP)
Gastrointestinal disorders: Fundic gland polyps
Disorders of the musculoskeletal system: Bone fracture
Cutaneous and systemic lupus erythematosus
Disorders affecting the skin and subcutaneous tissues: Severe dermatologic reactions including bullous and other drug eruptions of the skin
Black Box Warning:
None
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
It suppresses basal and induced gastric acid output in a dose-dependent manner by inhibiting the hydrogen ions, pottasium ions, ATPase of the coated stomach cells.
Pharmacodynamics:
It is a gastric proton pump inhibitor, is employed in the treatment of gastrointestinal ulcers, GERD symptoms.
Pharmacokinetics:
Absorption
The bioavailability is 52%
The time to achieve peak effect is 2-5 hours
Distribution
Protein-bound is 96.3%
Metabolism
Hepatic metabolism
Elimination and Excretion
The drug is excreted 10% in feces and 90 % in urine.
Half-life: 1-2 hour
Administration:
It is administered orally before thirty minutes of meals.
Patient information leaflet
Generic Name: rabeprazole
Pronounced:
Why do we use rabeprazole?
Rabeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production and is used to treat various acid-related gastrointestinal conditions. It is commonly prescribed for gastroesophageal reflux disease (GERD), healing erosive esophagitis, and managing gastric and duodenal ulcers. In cases of Helicobacter pylori infection, it is used with antibiotics to promote ulcer healing. Rabeprazole is also indicated for Zollinger-Ellison syndrome and the prevention of NSAID-induced gastric ulcers. Off-label, it may be used for functional dyspepsia and stress ulcer prevention in high-risk patients.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
